Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial
Sarah B. Goldberg(Yale University), Kurt A. Schalper(Yale University), Scott Gettinger(Yale University), Amit Mahajan(Yale University), Roy S. Herbst(Yale University), Anne C. Chiang(Yale University), Rogério Lilenbaum(Yale University), Frederick H. Wilson(Yale University), Sacit Bulent Omay(Yale University), James B. Yu(Yale University), Lucia B. Jilaveanu(Yale University), Thuy Tran(Yale University), Kira F. Pavlik(Yale University), Elin Rowen(Yale University), Heather Gerrish(Yale University), Annette Komlo(Yale University), Richa Gupta(Yale University), Hailey Wyatt(Yale University), Matthew Ribeiro(Yale University), Yuval Kluger(Yale University), Geyu Zhou(Yale University), Wei Wei(Yale University), Veronica Chiang(Yale University), Harriet M. Kluger(Yale University)
Cited by 538Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis